C O M M U N I C A T I O N S
Scheme 1
carbons 2′′-5′′, indicating that epimerization had occurred at C-6′′
and the new compound was 1b.15 In the case of compound 2a,
however, the 1H NMR signals of the two species were not
sufficiently separated to employ this technique. Instead, a nonste-
reoselective synthesis was used to generate an authentic 1.8:1
mixture of 2a/2b.15 A comparison of the 1H- and 31P NMR spectra
of the enzymatic mixture to that of the synthetic mixture confirmed
that the new product was 2b (Figure 2). Furthermore, when the
synthetic 1.8:1 mixture of 2a/2b was incubated with AGME, it was
converted into an equimolar mixture. The ability of 1 and 2 to serve
as substrates for AGME rules out all mechanisms that require
oxidation at C-4′′ or C-7′′ (paths A and C).
flexibility with regard to the position of oxidation is somewhat
reminiscent of the reaction catalyzed by CDP-tyvelose 2-epimerase,
an SDR family member that is thought to employ transient oxidation
at C-2′′.25,26
Acknowledgment. This work was supported by the Canadian
Institutes of Health Research (M.E.T.) and NCMHD/NIH (W.G.C.).
Supporting Information Available: Experimental procedures, 1H
NMR spectra of sugar nucleotides, and time courses of enzymatic
reactions. This material is available free of charge via the Internet at
As AGME is a member of the SDR superfamily, one might
expect it would utilize a strategy involving transient oxidation at
C-4′′.12,13 In particular, a notable similarity exists between the first
two steps in path C and those employed by the sugar nucleotide
4,6-dehydratases.18-21 However, both the solvent isotope incorpora-
tion studies and the deoxy-analogue studies indicate that transient
oxidation actually occurs at C-6′′. Thus, AGME appears to employ
a nonstereospecific oxidation/reduction mechanism (path B). As
with other SDR family members, at least one of the required acid/
base residues would likely be supplied by the conserved triad,
Ser116, Tyr140, Lys144.9 This strategy is conceptually similar to
that of the SDR enzyme UDP-galactose 4-epimerase; however, both
the position of oxidation and the required reorientation of the
oxidized intermediate are quite different.6,22-24 This display of
References
(1) Valvano, M. A.; Messner, P.; Kosma, P. Microbiology 2002, 148, 1979-
1989.
(2) Raetz, C. R. H.; Whitfield, C. Annu. ReV. Biochem. 2002, 71, 635-700.
(3) Coleman, W. G., Jr.; Leive, L. J. Bacteriol. 1979, 139, 899-910.
(4) Vaara, M. Antimicrob. Agents Chemother. 1993, 37, 354-356.
(5) Taylor, P. W. Microbiol. ReV. 1983, 47, 46-83.
(6) Samuel, J.; Tanner, M. E. Nat. Prod. Rep. 2002, 19, 261-277.
(7) Allard, S. T. M.; Giraud, M.-F.; Naismith, J. H. Cell. Mol. Life Sci. 2001,
58, 1650-1665.
(8) Ni, Y.; McPhie, P.; Deacon, A.; Ealick, S.; Coleman, W. G., Jr. J. Biol.
Chem. 2001, 276, 27329-27334.
(9) Deacon, A. M.; Ni, Y. S.; Coleman, W. G., Jr.; Ealick, S. E. Structure
2000, 8, 453-461.
(10) Ding, L.; Seto, B. L.; Ahmed, S. A.; Coleman, W. G., Jr. J. Biol. Chem.
1994, 269, 24384-24390.
(11) A structure of AGME complexed with ADP-R-D-glucose is available (ref
9); however, the electron density of the hexose moiety was disordered
and difficult to interpret. This is likely the result of having the incorrect
stereochemistry at both C-1′′ and C-2′′ of the substrate analogue, and it
complicates any mechanistic interpretations regarding the position of
transient oxidation.
(12) Field, R. A.; Naismith, J. H. Biochemistry 2003, 42, 7637-7647.
(13) Tanner, M. E. Curr. Org. Chem. 2001, 5, 169-192.
(14) Zamayatina, A.; Gronow, S.; Puchberger, M.; Graziani, A.; Hofinger, A.;
Kosma, P. Carbohydr. Res. 2003, 338, 2571-2589.
(15) See Supporting Information for details.
(16) Tanner, M. E. Acc. Chem. Res. 2002, 35, 237-246.
(17) Tanner, M. E.; Kenyon, G. L. In ComprehensiVe Biological Catalysis;
Sinnott, M., Ed.; Academic Press: San Diego, 1998; Vol. II, pp 7-41.
(18) He, X. M.; Agnihotri, G.; Liu, H.-W. Chem. ReV. 2000, 100, 4615-4661.
(19) Somoza, J. R.; Menon, S.; Schmidt, H.; Joseph-McCarthy, D.; Dessen,
A.; Stahl, M. L.; Somers, W. S.; Sullivan, F. X. Structure 2000, 8, 123-
135.
(20) Hegeman, A. D.; Gross, J. W.; Frey, P. A. Biochemistry 2002, 41, 2797-
2804.
(21) Beis, K.; Allard, S. T. M.; Hegeman, A. D.; Murshudov, G.; Philp, D.;
Naismith, J. H. J. Am. Chem. Soc. 2003, 125, 11872-11878.
(22) Wei, Y.; Lin, J.; Frey, P. A. Biochemistry 2001, 40, 11279-11287.
(23) Berger, E.; Arabshahi, A.; Wei, Y.; Schilling, J. F.; Frey, P. A.
Biochemistry 2001, 40, 6699-6705.
(24) Thoden, J. B.; Holden, H. M. Biochemistry 1998, 37, 11469-11477.
(25) Koropatkin, N. M.; Liu, H.-W.; Holden, H. M. J. Biol. Chem. 2003, 278,
20847-20881.
(26) Hallis, T. M.; Zhao, Z.; Liu, H.-W. J. Am. Chem. Soc. 2000, 10493-10503.
Figure 2. 31P-NMR spectra illustrating the epimerization of 2a.
JA0485659
9
J. AM. CHEM. SOC. VOL. 126, NO. 29, 2004 8879